Needham analyst Laura Martin reiterates Viant Technology (NASDAQ:DSP) with a Buy and maintains $7.5 price target.
Pfizer’s COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows
According to a new observational study published in the New England Journal of Medicine, Pfizer Inc's (NYSE: PFE) COVID-19 treatment, Paxlovid, only worked among patients 65 years of age or older, with